{
    "2018-04-09": [
        [
            {
                "time": "2018-01-02",
                "original_text": "AbbVie shares jump 2.2% on news of positive results in rheumatoid arthritis drug trial",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "shares",
                        "jump",
                        "positive results",
                        "rheumatoid arthritis",
                        "drug trial"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis",
                "features": {
                    "keywords": [
                        "Upadacitinib",
                        "Phase 3 Study",
                        "Rheumatoid Arthritis",
                        "Superiority",
                        "Adalimumab"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "3 Reasons This Clinical-Stage Biotech Is an Incredible Bargain",
                "features": {
                    "keywords": [
                        "Clinical-Stage",
                        "Biotech",
                        "Bargain"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Merck eyes best day since 2016, gains help fuel pharma rally",
                "features": {
                    "keywords": [
                        "Merck",
                        "best day",
                        "gains",
                        "pharma rally"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}